SCHEMBL982682

SCHEMBL982682

NN=C(Nc1cccc(Cl)c1F)c1cccnc1N

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PABPC1 P11940 1/20 0.40
EIF4H Q15056 1/20 0.40
GRM4 Q14833 1/20 0.39
SLC40A1 Q9NP59 1/20 0.39
KDR P35968 1/20 0.38
DHODH Q02127 1/20 0.38
PRKCI P41743 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
NAPRT Q6XQN6 1/20 0.37
SHMT2 P34897 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
GAA P10253 1/20 0.35
HTT P42858 1/20 0.35
CASP3 P42574 1/20 0.34
SENP8 Q96LD8 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
MAPK13 O15264 1/20 0.34
MAPK12 P53778 1/20 0.34
MAPK11 Q15759 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL982681 1.00 PABPC1 (0.40) PABPC1EIF4HGRM4SLC40A1KDR
SCHEMBL11946796 1.00 PABPC1 (0.40) PABPC1EIF4HGRM4SLC40A1KDR
SCHEMBL985507 0.87 PRKCI (0.39) SLC40A1PRKCINAPRTSHMT2HTT
SCHEMBL985508 0.87 PRKCI (0.39) SLC40A1PRKCINAPRTSHMT2HTT
SCHEMBL982424 0.87 GAA (0.46) PABPC1EIF4HKDRDHODHPRKCI
SCHEMBL982425 0.87 GAA (0.46) PABPC1EIF4HKDRDHODHPRKCI
SCHEMBL985905 0.84 ATR (0.36) GRM4SLC40A1PRKCIPDE4B
SCHEMBL985904 0.84 ATR (0.36) GRM4SLC40A1PRKCIPDE4B
SCHEMBL985515 0.82 PRKCI (0.55) PABPC1EIF4HGRM4KDRPRKCI
SCHEMBL982684 0.75 NAPRT (0.37) PABPC1EIF4HGRM4SLC40A1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232406-B2 c-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-31 US disclosed
US-7872031-B2 c-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-18 US disclosed
EP-2004625-B1 C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS VERTEX PHARMA (US) 2009-12-30 EP disclosed
US-20070254868-A1 C-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254868-A1 C-MET protein kinase inhibitors MET, PRKCH, ABL1 PABPC1 1478/4885EIF4H 906/4885GRM4 2460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.